Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37 results about "Opioid peptide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Opioid peptides are peptides that bind to opioid receptors in the brain; opiates and opioids mimic the effect of these peptides. Such peptides may be produced by the body itself, for example endorphins. The effects of these peptides vary, but they all resemble those of opiates. Brain opioid peptide systems are known to play an important role in motivation, emotion, attachment behaviour, the response to stress and pain, and the control of food intake.
Method for preparing wheat protein source opioid peptide by enzymolysis of wheat protein
InactiveCN101717805AImprove utilizationHigh opioid activityFermentationFiltration membraneOpioid peptide
The invention relates to a method for preparing a wheat protein source opioid peptide by the enzymolysis of wheat protein, belonging to the technical field of wheat protein deep processing. The method comprises the following steps of: taking wheat protein as raw material; then adding water to achieve a certain mass percent and regulating to a certain temperature and pH; firstly, adopting pepsin to carry out enzymolysis; then changing enzymolysis conditions; adopting trypsinase or trypsogen to carry out enzymolysis; regulating pH to be neutral after hydrolysis is ended; inactivating enzyme, cooling and centrifuging; taking supernate, and then decoloring, separating with a 3000Da ultra-filtration membrane and drying, and finally obtaining the wheat protein source opioid peptide. Adopting a guinea-pig ileum method to determine the opioid activity shows that the prepared wheat protein source opioid peptide has obvious opioid activity, whereas the wheat protein of the raw material does not have opioid activity. The invention widens the application range of the wheat protein through preparing the wheat protein source opioid peptide by enzymolysis, thereby providing the theoretical basis and efficient path for promoting the deep development and utilization of the wheat protein.
Owner:JIANGNAN UNIV
Method for examining the involvement of opioid peptides in prurtis
InactiveUS6984493B1Peptide/protein ingredientsMicrobiological testing/measurementOpioid AgonistOpioid peptide
A method for examining a disease includes measuring plural opioid peptides or opioid receptors in blood cell, body fluid, or tissue and calculating the ratio thereof. The method can be specifically applied to pruritic diseases. The invented method for examination can determine whether opioids are involved in a pruritic disease and can determine whether therapy with an opioid agonistic and / or antagonistic antipruritus agent is appropriate or not.
Owner:TORAY IND INC
Methods Related to the Treatment of Neurodegenerative and Inflammatory Conditions
The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and / or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.
Owner:UNITED STATES OF AMERICA
Methods related to the treatment of neurodegenerative and inflammatory conditions
Owner:UNITED STATES OF AMERICA
Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment
The invention provides novel inclusion complexes of highly potent opioid peptide of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin, pharmaceutical preparations containing these inclusion complexes of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin derivatives, the complexes being better soluble in water and having improved biopharmaceutical properties such as lesser toxicity, better analgesic action and non-addiction properties.
Owner:COUNCIL OF SCI & IND RES
K receptor opioid peptides
Peptides which exhibit high selectivity for the kappa opioid receptor (KOR) and long duration of peripheral action without significant entry into the brain are created which are sequences of four D-isomer amino acid residues having a C-terminus which is a mono- or di-substituted amide. Representative compounds, which have an affinity for the KOR at least 1,000 times their affinity for the mu opioid receptor and an ED50 of not greater than about 0.5 mg / kg, include H-D-Phe-D-Phe-D-Nle-D-Arg-NHEt, H-D-Phe-D-Phe-D-Nle-D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NHPr, H-D-Phe-D-Phe-D-Nle-D-Arg-thiomorpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NEt2, H-D-Phe-D-Phe-D-Nle-D-Arg-NHMe, H-D-Phe-D-Phe-D-Leu-D-Orn-morpholinyl, H-D-4Fpa-D-Phe-D-Nle-D-Arg-NH-4-picolyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-cyclopropyl, H-D-Ala-(2Thi)-D-3, 4Cpa-D-Leu-D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Gmf-morpholinyl, H-D-Phe-D-Phe-D-Leu-D-Orn-NH(Aeb), H-D-Phe-D-Phe-D-Leu-D-Lys-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-piperazinyl, and H-D-Phe-D-Phe-D-Nle-D-Arg-NH(Hoh).
Owner:CARA THERAPEUTICS
Composition for degrading opioid peptide
PendingCN111787933AMedication with peace of mindLess prone to side effectsNervous disorderBacteriaOpioid peptideMicrobiology
Owner:MORINAGA MILK IND CO LTD
Nanoparticle tumour vaccines
The present invention provides a vaccine for the prophylactic or therapeutic treatment of a tumour in a mammalian subject, as well as methods of using the vaccine, including in treatment of tumours and in generating a CTL response. The vaccine comprises a plurality of nanoparticles and a pharmaceutically acceptable carrier, salt or diluent. The nanoparticles comprise a core comprising a metal and / or a semiconductor atom; and a corona comprising a plurality of ligands covalently linked to the core, wherein at least a first ligand of said plurality comprises a carbohydrate moiety that iscovalently linked to the core via a first linker, and wherein at least a second ligand of said plurality comprises an epitopic peptide that is covalently linked to the core via a second linker, said second linker comprising a peptide portion and a non-peptide portion, wherein said peptide portion comprises the sequence X1X2Z1, wherein: X1 is an amino acid selected from A and G; X2 is an amino acid selected from A and G; and Z1 is an amino acid selected from Y and F, and wherein said epitopic peptide forms at least a portion of or is derived from a Tumour-Associated Antigen (TAA).
Owner:MIDATECH LTD +1
K receptor opioid peptides
Peptides which exhibit high selectivity for the kappa opioid receptor (KOR) and long duration of peripheral action without significant entry into the brain are created which are sequences of four D-isomer amino acid residues having a C-terminus which is a mono- or di-substituted amide. Representative compounds, which have an affinity for the KOR at least 1,000 times their affinity for the mu opioid receptor and an ED50 of not greater than about 0.5 mg / kg, include H-D-Phe-D-Phe-D-Nle-D-Arg-NHEt, H-D-Phe-D-Phe-D-Nle-D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NHPr, H-D-Phe-D-Phe-D-Nle-D-Arg-thiomorpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NEt2, H-D-Phe-D-Phe-D-Nle-D-Arg-NHMe, H-D-Phe-D-Phe-D-Leu-D-Orn-morpholinyl, H-D-4Fpa-D-Phe-D-Nle-D-Arg-NH-4-picolyl, H-D-Phe-D-Phe-D-Nle-D-Arg-NH-cyclopropyl, H-D-Ala-(2Thi)-D-3, 4Cpa-D-Leu-D-Arg-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Gmf-morpholinyl, H-D-Phe-D-Phe-D-Leu-D-Orn-NH(Aeb), H-D-Phe-D-Phe-D-Leu-D-Lys-morpholinyl, H-D-Phe-D-Phe-D-Nle-D-Arg-piperazinyl, and H-D-Phe-D-Phe-D-Nle-D-Arg-NH(Hoh).
Owner:CARA THERAPEUTICS
Tic-containing opioid dipeptide derivatives useful as analgesics
InactiveUS6150335AImprove performanceReceptor selectivityNervous disorderDipeptide ingredientsOpioid AgonistDipeptide
PCT No. PCT / SE97 / 02156 Sec. 371 Date Apr. 1, 1998 Sec. 102(e) Date Apr. 1, 1998 PCT Filed Dec. 18, 1997 PCT Pub. No. WO98 / 28327 PCT Pub. Date Jul. 2, 1998Use of a compound of the formula I for the manufacture of a medicament for the treatment of pain. The compounds are delta opioid agonists and thus useful in the treatment of pain without the requirement of co-application of a mu opioid agonist.
Owner:ASTRAZENECA AB
Opioid peptide for source of Alphas1-casein and preparation method thereof
InactiveCN101525376AGood anti-fatigue effectInhibition of voluntary contractionPeptide preparation methodsFermentationForeign proteinAlcohol
The invention discloses an opioid peptide for source of Alphas1-casein and a preparation method thereof. The preparation method comprises the following steps: pepsin is added into substrate, the pH value is adjusted to 2.0, enzymolysis is carried out to the obtained mixture for 2.5h at the temperature of 42 DEG C; wherein the substrate is Alphas1-casein solution with the concentration of 3 percent (w / v); the proportion of the pepsin and the Alphas1-casein is 1:30 (w / w); the enzymatic hydrolyzate adopts alcohol with the concentration of 80 percent for settling foreign protein, and the supernatant fluid is taken; and then a SephadexG-50 chromatography column is selected to carry out separation and chromatography to the supernatant fluid so as to collect a third peak. Fine separation and chromatography are carried out to the collected fluid by a SephadexG-15 chromatography column so as to collect a fourth peak; and after freeze-drying, the opioid peptide for source of Alphas1-casein is obtained. The obtained opioid active peptide corresponds to 144-158 sequence YFYPE LFRQFYQLDA of the Alpha-S1-casein, the molecular weight is 2252.48. The peptide can restrict autonomous contraction of ileum and has obvious effects of analgesis and fatigue resistance.
Owner:TIANJIN UNIV OF COMMERCE
Exogenous opioid peptide-degrading enzyme
InactiveUS20140219982A1Efficient degradationStrong degradation activityNervous disorderPeptide/protein ingredientsWheat glutelinOpioid peptide
The present invention is intended to provide a means for efficiently degrades exogenous opioid peptides. Provided is an exogenous opioid peptide-degrading enzyme preparation which contains one or more components selected from the group consisting of enzyme preparations from Penicillium citrinum, Aspergillus oryzae, and Aspergilius melleus, and exhibits a degradation activity for a wheat gluten-derived opioid peptide and a casein-derived opioid peptide.
Owner:AMANO ENZYME INC
Method of producing a novel opioid peptide
InactiveUS20120004180A1Good analgesic effectConserve and increases their analgesic activityNervous disorderTetrapeptide ingredientsPharmacophoreRheumatism
The use of opioid peptides of a novel structure is claimed which, in addition to a pharmacophore, additionally contain structural elements reactive with tachykinin receptors. Due to the synergistic reactivity of the opioid with an additional element, an increased analgesic activity is obtained facilitating protracted effective use due to decreased drug tolerance effects. The drugs may particularly be of use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatism, gout, neurodegenerative states, post-surgical and post-traumatic inflammations or ones induced by tumours.
Owner:LIPKOWSKI ANDREJ
Methods of hydrolyzing soyabean protein to produce exorphins
InactiveCN101691596BOpioid activeStrong physiological functionFermentationOpioid peptideProteolytic enzymes
The invention relates to methods of hydrolyzing soyabean protein to produce exorphins, belonging to the method of hydrolyzing the soyabean protein to produce special peptide and aiming at solving the problem that the prior method of the soyabean protein to produce the opioid peptide ignores the physiological function and the safety danger of the opioid peptide. The four methods of hydrolyzing thesoyabean protein to producing the exorphins are implemented in corresponding conditions by using parenzyme / alkaline enzyme, parenzyme / neutral enzyme, pancreatic alkaline enzyme / neutral enzyme and acid proteolytic enzyme / pepsinum. The four methods of synchronously hydrolyzing the soyabean protein to produce exorphins ensure the condition of producing the exorphins and the amount of the produced exorphins and lays a foundation for the safety of the post processing of the soyabean protein and the development of the soybean peptide food.
Owner:HARBIN UNIV OF COMMERCE
Composition for Degrading Opioid Peptide
InactiveUS20210100853A1Difficult to provideNot restrict dietary habitNervous disorderBacteriaBiotechnologyBifidobacterium
Owner:MORINAGA MILK IND CO LTD
Novel macrocyclic opioid peptides
The invention relates to macrocyclic peptides and pharmaceutical compositions thereof. The invention further provides macrocyclic tetrapeptides comprising sarcosine. The invention further relates to pharmaceutical compositions for modulating opioid receptor activity. The macrocyclic tetrapeptides provided herein are useful in treating diseases or disorders relating to the activity of one or more opioid receptors, such as neurological disorders.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Idr peptide compositions and use thereof for treatment of th2-dysregulated inflammatory conditions
A composition for treating or preventing a Th2-dysregulated inflammatory condition wherein the composition comprises a therapeutically effective amount of one or more IDR peptides. Use of IDR peptides or a composition comprising IDR peptides for treating or preventing a Th2-dysregulated inflammatory condition. The Th2-dysregulated inflammatory condition includes allergy or atopy, for example allergic asthma.
Owner:UNIVERSITY OF MANITOBA
Anti-opioid peptide, antagonistic peptide thereof and use thereof
InactiveCN101323641BEasy to degradePromote degradationNervous disorderPeptide/protein ingredientsAntagonismOpiate Peptides
The invention discloses an anti-opiate peptide, an antagonistic peptide and an application thereof. The anti-opiate peptide is one of amino-acid residue sequences as follows: 1) SEQ ID NO: 1 in the sequence table; 2) substitution and deletion of one to ten amino-acid residues, or addition of polypeptide which has the functions of antagonism for morphine and antinociception is carried out on the amino-acid residue sequence of SEQ ID NO: 1 in the sequence table. The antagonistic peptide is one of the following amino-acid residue sequences: 1) SEQ ID NO: 5-7 in the sequence table; 2) substitution and deletion of one to ten amino-acid residues, or addition of polypeptide which can enhance the analgesic effect of the morphine, reverse the tolerance of the morphine and / or weaken or eliminate the effect of abstinence symptoms is carried out on the amino-acid residue sequence of SEQ ID NO: 5-7 in the sequence table. The anti-opiate peptide, the active fragment thereof and the antagonistic peptide of the invention can play an important role in the preparation fields of medicine and rehabilitation drugs and have wide application prospect.
Owner:PEKING UNIV
Bifunctional peptide based on opioid peptide and cannabis sativa peptide as well as preparation method and application thereof
ActiveCN112961249AHigh analgesic activityEffective analgesic effectNervous disorderPeptide/protein ingredientsCannabisOpioid peptide
The invention discloses a bifunctional peptide based on opioid peptide and cannabis sativa peptide as well as a preparation method and application thereof. The bifunctional peptide is a brand-new bifunctional peptide constructed based on an N-terminal sequence of opioid peptide DALDA and a C-terminal sequence of cannabis sativa peptide (m) VD-Hpalpha-NH2. Compared with the prior art, the analgesic activity of OCP 001 and OCP 002 in vivo is enhanced, an analgesic effect which is more effective than that of parent molecules is generated, the problem of analgesic tolerance existing in opioid and hemp agonists and the parent molecules is solved, an analgesic effect in a non-tolerance form is generated, and the bifunctional peptide can be used for treating acute pain and pathological pain.
Owner:LANZHOU UNIVERSITY
Active fragment of anti-opioid peptide
Owner:PEKING UNIV
Bifidobacterium genus bacterium
ActiveUS11504407B2Avoid absorptionEfficiently decompose opioid peptidesMilk preparationBacteriaBifidobacteriumOpioid peptide
Owner:MORINAGA MILK IND CO LTD
Difunctional D-amino acid modified opioid peptide compound as well as synthesis method and application thereof
PendingCN110776555AImprove resistance to enzymatic hydrolysisImprove bioavailabilityAntipyreticAnalgesicsPharmacometricsAmino acid peptide
The invention discloses a difunctional D-amino acid modified opioid peptide compound, a synthesis method of the compound and application of the series of analogues to preparation of analgesics. The synthesis method comprises the steps of synthesizing solid-phase carrier peptide resin; on the solid-phase carrier, sequentially inoculating corresponding amino acid according to the sequence from a C end to an N end of a polypeptide sequence; and performing peptide resin after treatment, cutting peptide, extracting peptide and performing preparation and purification. The synthesis method is simpleand convenient, easy to operate, short in condensation time, capable of perform large-scale synthesis and easy in purification. Sites, which are easily identified by enzyme and subjected to digestion,in a modified sequence are selectively replaced, high mu-opioid receptor can be maintained, the ability of resisting hydrolysis of enzyme in a living body can be obviously improved, the duration timeof analgesic activity and analgesic effect is prolonged, the bioavailability is effectively improved, and good pharmacological activity and potential clinical application value are achieved.
Owner:王锐
Method of producing a novel opioid peptide
InactiveUS8877891B2Good analgesic effectConserve and increases their analgesic activityNervous disorderTetrapeptide ingredientsPharmacophoreRheumatism
The use of opioid peptides of a novel structure is claimed which, in addition to a pharmacophore, additionally contain structural elements reactive with tachykinin receptors. Due to the synergistic reactivity of the opioid with an additional element, an increased analgesic activity is obtained facilitating protracted effective use due to decreased drug tolerance effects. The drugs may particularly be of use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatism, gout, neurodegenerative states, post-surgical and post-traumatic inflammations or ones induced by tumors.
Owner:LIPKOWSKI ANDREJ
Active fragment of anti-opioid peptide
The invention discloses an active fragment of an anti-opioid peptide and an antagonistic peptide and application thereof. The anti-opioid peptide is one of the following amino acid residue sequences: 1) SEQ ID No:1 in a sequence list; 2) SEQ ID No:3-5; and 3) a polypeptide which has an antagonistic morphine damage resisting function and is formed by substituting, deleting or adding one to ten amino acid residues in the amino acid residue sequence of SEQ ID No:1 and SEQ ID No:3-5 in the sequence list. The antagonistic peptide is one of the following amino acid residue sequences: 1) SEQ ID No:9-11 in the sequence list; and 2) a polypeptide which has functions of enhancing morphine analgesis, reversing morphine resistance and / or weakening or eliminating withdrawal symptoms and is formed by substituting, deleting or adding one to ten amino acid residues in the amino acid residue sequence of SEQ ID No:9-11 in the sequence list. The anti-opioid peptide and the active fragment and antagonistic peptide of the anti-opioid peptide can play important roles in the field of medicine or the field of the preparation of rehabilitation medicaments and have wide application prospect.
Owner:PEKING UNIV
Antagonistic peptide of anti-opioid peptide and application thereof
InactiveCN102127152AEasy to degradePromote degradationNervous disorderPeptide/protein ingredientsAbstinenceOpioid peptide
The invention discloses anti-opioid peptide, and antagonistic peptide and application thereof. The anti-opioid peptide has one of the following amino acid residue sequences: 1) SEQ ID NO:1 in a sequence table; and 2) the amino acid residue sequence shown as the SEQ ID NO:1 in the sequence table is replaced and deleted by 1 to 10 amino acid residues or added with polypeptide with the effect of resisting morphine damages. The antagonistic peptide has one of the following amino acid residue sequences: 1) SEQ ID NO:5-7 in a sequence table; and 2) the amino acid residue sequence shown as the SEQ ID NO:5-7 in the sequence table is replaced and deleted by 1 to 10 amino acid residues or added with polypeptide with the effects of enhancing morphine analgesia, reversing morphine tolerance and / or weakening or eliminating abstinence syndromes. The anti-opioid peptide and an active segment and the antagonistic peptide thereof exert an important effect in the field of preparation of medicinal and drug treatment medicaments and have wide application prospects.
Owner:PEKING UNIV
Anti-opioid peptide antagonist peptide and application thereof
The invention discloses an anti-opioid peptide,antagonist peptide and application thereof. The anti-opioid peptide is polypeptide formed by the way that one of the following amino acid residue sequences: 1) SEQ ID NO: 1 in the sequence table; 2) SEQ ID NO: 3-5; 3) amino acid residue sequences of SEQ ID NO: 1, SEQ ID NO: 3-5 in the sequence table are subject to substitution, deletion or addition of one to ten amino acid residues to have antagonist morphine anti-harm effect. The antagonist peptide thereof is polypeptide formed by the way that one of the following amino acid residue sequences: 1) SEQ ID NO: 9-11 in the sequence table; 2) amino acid residue sequences of SEQ ID NO: 9-11 in the sequence table is subject to substitution, deletion or addition of one to ten amino acid residues to have effects of enhancing morphine analgesia, reversing morphine tolerance and / or reducing or eliminating abstinence symptom. The anti-opioid peptide and active segment thereof and antagonist peptide can play important role in the medicinal and rehabilitation medicine preparation field and has wide application prospect.
Owner:PEKING UNIV
Methods related to the treatment of neurodegenerative and inflammatory conditions
Owner:UNITED STATES OF AMERICA
Anti-opium peptide and antagonistic peptide and its application
InactiveCN101113172BReduce dosageEasy to degradeNervous disorderPeptide/protein ingredientsOpioid peptidePharmaceutical drug
Owner:PEKING UNIV
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com